BUZZ-<a href="https://laohu8.com/S/APGE">Apogee Therapeutics</a> rises as asthma drug shows promise in early trial** Shares of drug developer Apogee Therapeutics APGE.O rise 1.66% to $78.35 premarket
** Co says its experimental drug zumilokibart showed strong results in an early-stage trial for adults with mild-to-moderate asthma
** Zumilokibart cut airway inflammation in the adults - AGPE
** Effect lasted up to 32 weeks after a single dose; no serious side effects reported, says co
** Co's zumilokibart also being tested for atopic dermatitis, a chronic skin condition - APGE
** Apogee expects more trial data this year and aims to start late-stage studies next year
** As of last close, stock up ~3% over the past year
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.